IDEXX Laboratories Inc
- Market cap
- 39.92B
- P/E (TTM)i
- 35.61
- P/Bi
- 24.75
- EPSi
- 13.08
- Div yieldi
- 0.00%
- 52W posi
- 2%
Anonymous reader poll. Unscientific, not investment advice.
Shares of IDEXX Laboratories Inc closed at 506.67, down 1.70%. That leaves the company valued at approximately 39.92B, the #543 most valuable US-listed company we track. Valuation-wise, the P/E sits at 36.70, 28% below the five-year average of 50.85. Wall Street's 7-analyst consensus lands on Buy, with a price target averaging 699.17 (+38% from here). Against a 52-week band of 500.61-769.98, the shares are currently 2% of the way up.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 weeks.
- Its last 3 Sell calls were actually followed by a +4% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -15.2% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation C
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 37.0x | Better than 20% |
| Forward P/E | 33.2x | Better than 16% |
| Price / Sales | 9.0x | Better than 14% |
| P/E vs own 5-yr range | 2nd pctl | Better than 94% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 8.5% | Better than 58% |
| Net income CAGR (3Y) | 16.0% | Better than 68% |
| Free cash flow CAGR (3Y) | 39.5% | Better than 83% |
Profitability A+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 61.8% | Better than 76% |
| Operating margin | 31.6% | Better than 87% |
| Net margin | 24.6% | Better than 82% |
| Return on equity | 66.2% | Better than 93% |
| Return on invested capital | 42.1% | Better than 98% |
Momentum D+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -7.6% | Better than 34% |
| 6-month return | -8.3% | Better than 25% |
| 12-month return (ex latest month) | -14.7% | Better than 17% |
| Distance below 52-week high | 31.5% | Better than 25% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.2x | Better than 39% |
| Debt to assets | 29.1% | Better than 50% |
| Interest coverage | 35.1x | Better than 86% |
| Free cash flow / net income | 98.5% | Better than 38% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 57.1% | Better than 31% |
| Upside to average target | 32.7% | Better than 65% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 515.41
- Open
- 513.31
- Day range
- 501.17 - 515.17
- Avg price
- 507.52
- Volume
- 716.45K
- Turnover
- 363.61M
- Turnover ratei
- 0.91%
- Volume ratioi
- 1.61
- Amplitudei
- 2.72%
- 52-week rangei
- 500.61 - 769.98
Valuation
- P/Ei
- 38.74
- P/E (TTM)i
- 35.61
- P/Bi
- 24.75
- EPSi
- 13.08
- Book value / shi
- 20.47
- Net profit
- 1.03B
- Net assets
- 1.61B
Share structure
- Market cap
- 39.92B
- Float capi
- 39.77B
- Shares out
- 78.78M
- Float sharesi
- 78.50M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
34.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-8.14M net over the window
Short interest
- Shares short
- 1.92M
- % of floati
- 2.43%
- Days to coveri
- 3.77
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of IDEXX Laboratories Inc (IDXX)?
IDEXX Laboratories Inc last traded at 506.67. The quote on this page refreshes every few seconds while US markets are open.
What is IDEXX Laboratories Inc's market cap?
About 39.92B.
What is the P/E ratio of IDEXX Laboratories Inc?
The trailing twelve-month P/E is 35.61, below its own 5-year average of 50.85 — toward the bottom of its historical range (1.52% percentile). See the Valuation tab for the full history.
Does IDEXX Laboratories Inc pay a dividend?
IDEXX Laboratories Inc does not currently pay a regular dividend.
Is IDEXX Laboratories Inc a buy according to analysts?
The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 699.17, which implies 38.0% upside from the current price. This is not investment advice.
What is IDEXX Laboratories Inc's StockVane Quant Rating?
The StockVane Momentum strategy currently rates IDEXX Laboratories Inc a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-08 05:47:24 · For reference only, not investment advice and not tailored to your situation.